BI 2536

DRUG9 trials

Sponsors

Boehringer Ingelheim, European Organisation for Research and Treatment of Cancer - EORTC

Conditions

Breast CancerCarcinoma, Non-Small-Cell LungCarcinoma, Small CellEndometrial CancerHead and Neck CancerLeukemia, Myeloid, AcuteLymphomaMelanoma (Skin)

Phase 1

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

CompletedNCT00243087

Boehringer IngelheimLymphoma

Start: 2005-07-31Updated: 2024-12-20

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

CompletedNCT02211859

Boehringer IngelheimNeoplasms

Start: 2004-08-31Updated: 2024-12-20

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

CompletedNCT02211833

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2006-10-31Updated: 2014-08-08

Phase 2

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

CompletedNCT00376623

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2006-07-25End: 2008-04-01Updated: 2022-06-21

BI 2536 Second Line Monotherapy in SCLC

CompletedNCT00412880

Boehringer IngelheimCarcinoma, Small Cell

Start: 2007-02-14End: 2008-06-30Updated: 2022-06-22

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

CompletedNCT00526149

European Organisation for Research and Treatment of Cancer - EORTCBreast Cancer, Endometrial Cancer, Head and Neck Cancer +3

Start: 2007-07-31Updated: 2013-10-07

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

CompletedNCT00701766

Boehringer IngelheimLeukemia, Myeloid, Acute

Start: 2006-10-31Updated: 2014-05-16

Phase II Study of BI 2536 in Prostate Cancer

CompletedNCT00706498

Boehringer IngelheimProstatic Neoplasms

Start: 2006-09-30Updated: 2014-05-16

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

CompletedNCT00710710

Boehringer IngelheimPancreatic Neoplasms

Start: 2006-08-01End: 2008-10-14Updated: 2022-05-04